Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis
- PMID: 34022453
- DOI: 10.1016/j.cgh.2021.05.028
Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis
Comment in
-
Reply.Clin Gastroenterol Hepatol. 2022 May;20(5):1189-1190. doi: 10.1016/j.cgh.2021.06.033. Epub 2021 Jun 29. Clin Gastroenterol Hepatol. 2022. PMID: 34214677 No abstract available.
Comment on
-
Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.Clin Gastroenterol Hepatol. 2022 Mar;20(3):525-534.e10. doi: 10.1016/j.cgh.2021.04.022. Epub 2021 Apr 19. Clin Gastroenterol Hepatol. 2022. PMID: 33887475 Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources